Appendix 4D - Half-year Financial Report - 31 December 2025

• Completed strategic transition to pure play commercialisation model
• Secured key regulatory approvals in UK, EU, and Australia
• Executed major commercial supply agreements in Europe and MENA

During the half-year, Memphasys completed a strategic transition to a pure play commercialisation model focused exclusively on the Felix™ System. The company realigned its operating structure, reduced annualised costs, and redeployed capital toward manufacturing, sales execution, and regulatory acceleration to support near-term revenue growth. Key milestones included securing regulatory approvals in the UK, EU, and Australia, enabling commercial activities in these markets. Memphasys executed a five-year European supply agreement with a major Italian fertility group, as well as an exclusive five-year MENA agreement, receiving initial orders. In India, the company executed its first supply deal under a go-direct strategy. In Japan, Memphasys continued to see recurring clinical utilisation and repeat orders for the Felix™ System. For the half-year, the group recorded a net loss of $2.34 million, an improvement from $2.97 million in the prior period, with $12,406 in operating revenue recognised.

The company expects average monthly cash burn to be approximately $250,000 following the December 2025 quarter as one-off costs fall away and revenue generation increases.

Memphasys is focused on executing its global commercial strategy, with a priority on driving recurring cartridge-based revenues through its direct sales model. The company is confident that commercial execution will support volumes in excess of minimum contractual commitments in Europe and the MENA region.